Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.67 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.38 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.33 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.33 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9789649 | 0.82 | BRD4 (0.59) | BRD4MAPTPOLB | |
| SCHEMBL17294311 | 0.78 | BRD4 (0.42) | BRD4ITGB1ITGA5ITGB3ITGB2 | |
| SCHEMBL1929098 | 0.78 | — | — | |
| SCHEMBL11110416 | 0.77 | BRD4 (0.41) | BRD4ITGB1ITGA5ITGB3ITGB2 | |
| SCHEMBL24630134 | 0.76 | BRD4 (0.61) | BRD4 | |
| SCHEMBL18821186 | 0.75 | — | — | |
| SCHEMBL21964862 | 0.75 | — | — | |
| SCHEMBL5709310 | 0.75 | — | — | |
| SCHEMBL15850804 | 0.74 | — | — | |
| SCHEMBL19357292 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106536489-B | Retinoid-related orphan receptor gamma modulators and uses thereof | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-3148975-B1 | PIPERAZINE DERIVATIVES AS ROR-GAMMA MODULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2018-11-28 | — | — | EP | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-9902735-B2 | Heteroaryl substituted compounds as RORγ inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-02-27 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| US-20170197978-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-13 | — | — | US | disclosed |
| EP-3148975-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015180612-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015180612-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | WO | disclosed |
| WO-2009038412-A2 | BETA-SECRETASE INHIBITING COMPOUNDS | LG LIFE SCIENCES, LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197978-A1 | NOVEL COMPOUNDS | RORC, RORB, RORA | BRD4 608/4885ITGB1 1491/4885ITGA5 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.